Bristol-Myers, Gilead Work on New Combo HIV Pill
October 27, 2011
Bristol-Myers Squibb Co. and Gilead Sciences Inc. announced Wednesday a deal to develop and sell a once-a-day HIV pill that combines a popular protease inhibitor (PI) with a boosting agent.
10.26.2011; Linda A. Johnson
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)